NEPH NEPHROS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1196298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY29.0%
TTM EPS YoY28.6%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR—
Margins
Gross margin60.5%
Operating margin8.5%
Net margin8.9%
FCF margin—
EBITDA margin9.0%
Returns
ROE16.9%
ROA13.4%
ROIC (approx.)22.5%
Asset turnover1.51x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $18.79M | $14.16M | $14.24M | $9.97M | $10.22M |
| Cost of revenue | $7.16M | $5.44M | $5.83M | $5.24M | $4.58M |
| Gross profit | $11.62M | $8.72M | $8.40M | $4.73M | $5.63M |
| R&D expense | $1.34M | $906,000 | $873,000 | $1.25M | $1.50M |
| SG&A expense | $9.00M | $7.68M | $8.91M | $7.59M | $7.20M |
| Operating income | $1.15M | $6,000 | -$1.59M | -$4.33M | -$3.25M |
| Interest expense | $1,000 | $1,000 | $2,000 | $20,000 | $41,000 |
| Pretax income | $1.21M | $89,000 | -$1.57M | — | — |
| Income tax | $12,000 | $15,000 | $0 | $0 | $0 |
| Net income | $1.19M | $74,000 | -$1.57M | -$7.38M | -$3.87M |
| EBITDA | $1.29M | $141,000 | -$1.38M | -$4.12M | -$3.06M |
| EPS (basic) | 0.11 | 0.01 | -0.15 | -0.73 | -0.41 |
| EPS (diluted) | 0.11 | 0.01 | -0.15 | -0.73 | -0.41 |
| Weighted avg. shares (diluted) | 10.97M | 10.60M | 10.39M | 10.30M | 10.02M |
| Balance sheet | |||||
| Cash & equivalents | $5.40M | $3.76M | $4.31M | $3.63M | $6.97M |
| Receivables | $2.41M | $1.78M | $1.50M | $1.29M | $1.64M |
| Inventory | $3.23M | $2.62M | $2.47M | $3.15M | $4.46M |
| Current assets | $11.22M | $8.30M | $8.40M | $8.26M | $13.63M |
| PP&E, net | $106,000 | $161,000 | $152,000 | $116,000 | $72,000 |
| Goodwill | $759,000 | $759,000 | $759,000 | $759,000 | $759,000 |
| Intangibles | $318,000 | $349,000 | $381,000 | $423,000 | $465,000 |
| Total assets | $13.64M | $11.21M | $11.86M | $11.00M | $17.65M |
| Current liabilities | $2.77M | $1.56M | $2.11M | $1.41M | $2.39M |
| Long-term debt | — | — | — | $71,000 | $343,000 |
| Total debt | — | — | — | $71,000 | $343,000 |
| Total liabilities | $3.44M | $2.62M | $3.50M | $2.12M | $2.90M |
| Shareholders' equity | $10.20M | $8.59M | $8.36M | $5.59M | $11.70M |
| Net debt | — | — | — | -$3.56M | -$6.63M |
| Shares outstanding | 10.64M | 10.54M | 10.54M | 10.30M | 10.26M |
| Cash flow statement | |||||
| Operating cash flow | $1.65M | -$492,000 | $827,000 | -$3.23M | -$1.42M |
| Capital expenditure | — | $55,000 | $75,000 | $137,000 | $36,000 |
| Free cash flow | — | -$547,000 | $752,000 | -$3.37M | -$1.45M |
| Investing cash flow | $0 | -$50,000 | -$75,000 | -$137,000 | -$85,000 |
| Financing cash flow | -$5,000 | -$5,000 | -$79,000 | $34,000 | $237,000 |
| Depreciation & amortization | $140,000 | $135,000 | $214,000 | $218,000 | $192,000 |
| Stock-based compensation | $296,000 | $153,000 | $1.05M | $982,000 | $1.26M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.